Overview


According to FutureWise analysis the market for moyamoya disease in 2023 is US$ 0.94 billion, and is expected to reach US$ 1.43 billion by 2031 at a CAGR of 5.42%.

Moyamoya Disease refers to a condition in which certain blood vessels in the brain become narrowed. Constriction and blood clots block blood flow (thrombosis). To compensate for blockage, collateral circulation forms around the blocked vessels. However, the collateral vessels are weak and susceptible to bleeding or aneurysm as well as thrombosis. These collateral vessels appear like a puff of smoke on angiography. Moyamoya can be diagnosed by itself if there are no other correlational conditions. If the collateral circulation and arterial constriction are bilateral, this is also possible. Moyamoya syndrome refers to unilateral arterial constriction. It can also occur when any of the conditions listed are present. Moyamoya syndrome can also be described as secondary to the primary condition. Occlusion of distal inner carotid arterial is the main cause. A "puff-of-smoke" appearance can be seen in angiography. Surgery bypass is the best option.

Moyamoya Disease (MMD), a chronic cerebrovascular disorder, is characterized by progressive stenosis in the internal carotid and abnormal vascular networks at the base of the brain. One of the most important signs of moyamoya is stroke.
Paralysis can occur in the arms, legs, and face. It can also lead to language impairment, temporary loss of nerve function, and paralysis. It can happen at any age, but it is more common in children aged 5-10 years and adults aged 30-50 years. Moyamoya is treated with anticoagulants, antiplatelet agents, and hematologic drugs. People are more health-conscious and aware. This has led to a rise in awareness, which has aided the growth of this market. This is also being controlled by both new and established marketers. For data collection, large sample sizes were used to suit the needs of both small and medium-sized businesses. The moyamoya gene has been discovered, but the pathogenesis has remained mysterious for six decades. ring finger protein 213 The RNF213 has been implicated. The vascular occlusion can continue even after it has started, despite medical treatment. This can lead to serious complications in some cases. transient ischemic attacks or multiple strokes that cause severe functional impairment, death, or both. Others may not experience any symptoms. Moyamoya's arterial constrictions are not like the ones in Atherosclerosis. Atherosclerosis is the occurrence of atherosclerosis. Walls Damage to arteries can lead to fat accumulation and immune cell loss, which in turn leads to the formation of fat-laden immune cells. Moyamoya is a condition in which the inner layer within the carotid arterial proliferates. Lumen. Additionally, blood clots can build up in the artery. This could lead to strokes.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Moyamoya Disease Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Moyamoya Disease Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Abbott
  • Pfizer Inc
  • AstraZeneca
  • Eli Lilly and Company
  • Abiogen Pharma S.p.A
  • Merck
  • Novartis AG
  • GlaxoSmithKline Plc
  • Regeneron Pharmaceuticals Inc
  • Boehringer Ingelheim
  • AbbVie

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Diagnosis

  • Cerebral Angiogram
  • MRI
  • CT Scan
  • Transcranial Doppler Ultrasound
  • PET Scan
  • Electroencephalography

By Treatment

  • Surgical
  • Non-Surgical
  • Medication

By Distribution Channel

  • Hospital Pharmacy
  • Drug Store
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Moyamoya Disease Market By Diagnosis, By Treatment, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Moyamoya Disease Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Moyamoya Disease Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Moyamoya Disease Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Moyamoya Disease Market, By Diagnosis Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Cerebral Angiogram
        2. MRI
        3. CT Scan
        4. Transcranial Doppler Ultrasound
        5. PET Scan
        6. Electroencephalography

  • 8.   Moyamoya Disease Market, By Treatment Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Surgical
        2. Non-Surgical
        3. Medication

  • 9.   Moyamoya Disease Market, By Distribution Channel Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Hospital Pharmacy
        2. Drug Store
        3. Retail Pharmacy
        4. Online Pharmacy

  • 10.   North America Moyamoya Disease Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 11.   Latin America Moyamoya Disease Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 12.   Europe Moyamoya Disease Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 13.   Asia Pacific Moyamoya Disease Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032

  • 14.   Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Abbott
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Pfizer Inc
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. AstraZeneca
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Eli Lilly and Company
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Abiogen Pharma S.p.A
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Merck
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Novartis AG
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. GlaxoSmithKline Plc
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Regeneron Pharmaceuticals Inc
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Boehringer ingelheim
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. AbbVie
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare
                   administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients